Xcout Intel
Umecrine Cognition
Umecrine Cognition AB is a Swedish clinical-stage pharmaceutical company based at the Karolinska Institutet Science Park in Solna, developing a novel class of drugs to treat neurological disorders of the brain.
Subscribe to see Umecrine Cognition’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Umecrine Cognition at a glance
Umecrine Cognition is a biotechnology company headquartered in Sweden. Its most recent funding round, Debt, raised $2.5M in July 2025. Xcout tracks 7 named people at Umecrine Cognition, including Anders Karlsson (CEO).
Umecrine Cognition leadership
- Anders KarlssonCEO
- Viktor DrvotaCEO and Chairman of the Board
- Torbjörn BäckströmFounder & Non-executive Director
- Anders BladhNon-executive Director
- Bruce F. ScharschmidtNon-executive Director
- John ÖhdNon-executive Director
1 more named person on record for Umecrine Cognition, with roles, board committees and tenure — see the full roster →
Umecrine Cognition funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Debt | $2.5M | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Umecrine Cognition competitors
A few of Umecrine Cognition's closest competitors — see the full list of competitors and alternatives →
Alzinova AB is a Swedish clinical-stage biopharmaceutical company that develops disease-modifying treatments and vaccines targeting Alzheimer's disease. Utilizing its proprietary AβCC Peptide technology, the company focuses on creating therapeutics for Alzheimer's patients to address high unmet medical needs in neurodegeneration.
BioArctic AB (publ) is an innovative Swedish research-based biopharma company headquartered in Stockholm, Sweden. Incorporated in 2000, it focuses on developing disease-modifying treatments for neurodegenerative diseases. The company is publicly traded and committed to corporate governance.
Ultimate Medicine AG is a Swiss preclinical biotechnology company headquartered in Zürich, focused on maximizing the healthspan of patients with Alzheimer's disease and other dementias by targeting novel toxic metabolites.
Recognify Life Sciences is a clinical-stage biotechnology company located in California, focusing on developing treatments for cognitive impairment associated with central nervous system disorders.
BioCrine AB is a drug pipeline and biotechnology research company headquartered in Solna, Sweden, operating in the endocrinology and therapeutic medical domains.
BioArctic AB is a Swedish biopharmaceutical company developing disease-modifying treatments for neurodegenerative disorders, particularly Alzheimer’s and Parkinson’s disease. It serves patients and healthcare systems through its own drug-development programs and partnerships with pharmaceutical companies, including Eisai.
Get Umecrine Cognition's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Umecrine Cognition in Xcout Intel
- 7 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access